Primary open-angle glaucoma (POAG) is characterized by chronic and progressive optic nerve degeneration and retinal ganglion cell loss, accompanied by corresponding visual field defects. Older age, positive family history, and African ancestry are well-known risk factors. POAG is highly prevalent in African Americans (AA), with a recent survey estimating that 9.2% of Philadelphian AA over age 50 have POAG.1 AA also have been implicated in prostate cancer.5–8

The V83I polymorphism is associated strongly with POAG in AA men and disrupts Aβ-binding to CO1. This region also interacts with a neuroprotective protein, UBQLN1. Keywords: glaucoma, mitochondrial DNA, genetic diseases, haplogroups, open-angle glaucoma
METHODS

Study Subject Recruitment

The baseline demographics, and inclusion and exclusion criteria of the POAAGG study have been described previously. Subjects were identified from within all comprehensive and subspecialty ophthalmology clinics at the University of Pennsylvania (Scheie Eye Institute, Perelman Center for Advanced Medicine, Mercy Fitzgerald Hospital), Lewis Katz School of Medicine at Temple University, and a private practice (Windell Murphy, MD). Subjects were age 35 years or older, and self-identified as Black, AA, or as having African ancestry. All eligible patients underwent an onsite ophthalmic exam and interview. The full onsite exam included: (1) verification of name, age, date of birth, street address, sex, and informed consent with signature; (2) completion of a questionnaire in-clinic; (3) evaluation of height and weight; (4) explanation of procedure for blood or saliva collection for DNA analysis; (5) visual acuity (VA) measured using the Snellen chart at 20 feet; (6) automated refraction with a Reichert Phoropter RS Automatic Refractor (Reichert Technologies, Depew, NY, USA) if the presented VA was not 20/20 in either eye, followed by manual refraction; (7) IOP measured with a Goldmann applanation tonometer; (8) anterior and posterior segment examinations by slit-lamp with a 90 diopter (D) lens for optic nerve examination and indirect ophthalmoscopy; (9) gonioscopy confirming the presence of an open-angle; (10) central corneal thickness and axial length measurements assessed with an ultrasonic A-scan/pachymeter DGH 4000B SBH 101 Computation module (DGH Tech, Inc., Exton, PA, USA); (11) visual field test using the Humphrey Automated Field Analyzer (Standard 24-2 Swedish interactive thresholding algorithm); (12) stereo disc photos and fundus photography using the Topcon TRC 50EX Retinal Camera (Topcom Corp. of America, Paramus, NJ, USA); and (13) optical coherence topography (OCT) using either Cirrus or Stratus OCT (Carl Zeiss Meditec, Dublin, CA, USA). The outcomes of the procedures and all diagnoses were discussed with the patient at the conclusion of the examination. All enrolled subjects provided a signed informed consent and genomic DNA, which was extracted from peripheral blood or saliva.

Glaucoma specialists classified subjects as cases, controls, or suspects. POAG cases were defined as having an open iridocorneal angle and: (1) characteristic glaucomatous optic nerve findings in one or both eyes consisting of at least one of the following: notching, neuroretinal rim thinning, excavation, or a nerve fiber layer defect; (2) characteristic visual field defects on two consecutive reliable visual field tests in at least one eye, which were consistent with the observed optic nerve defects in that eye, as determined by fellowship-trained glaucoma specialists; and (3) all secondary causes of glaucoma excluded. Normal controls were defined as subjects older than 35, without: (1) high myopia (greater than −8.00 D); (2) high presbyopia (+8.00 D); (3) family history of POAG; (4) abnormal visual field; (5) IOP greater than 21 mm Hg; (6) neuroretinal rim thinning, excavation, notching or nerve fiber layer defects; (7) optic nerves asymmetry; or (8) a cup-to-disc ratio difference between eyes greater than 0.2. Subjects classified as glaucoma suspects were excluded from all analyses. Research was approved by an institutional review board at the University of Pennsylvania, and was conducted in accordance with the Declaration of Helsinki. PCR, DNA Sequencing and Mutation Analysis

Amplicons corresponding to the MT-CO1 and MT-RNR2 genes had been PCR amplified and Sanger sequenced, with methods and results reported previously. The original Sanger sequencing cohort contained POAG cases, controls, and some glaucoma suspects (excluded from analyses). Because some subjects’ disease had progressed since the cohort was sequenced, subject disease status was updated to be current as of August 2016, before reanalysis for association with POAG by sex, and data from more recently enrolled subjects were included (total n = 2189; 1339 cases, 850 controls). Version 5.2 of Sequencher software was used to score sequencing chromatograms for missense variants. Missense variants were annotated using version 1.0 of the MitImpact resource (available in the public domain at http://mitimpact.css-men.deli.it/) and the MITOMAP compendium to identify potentially deleterious mutations.

Phylogeny and Localization of Amino Acid Replacements

Build 17 of PhyloTree (available in the public domain at www.phylotree.org) and the MITOMAP and MITOMASTER databases (available in the public domain at www.mitomap.org) were used to associate the observed mtDNA variants with mitochondrial haplogroups. The subcellular localizations of MT-CO1 missense mutations were predicted by sequence analysis using the UniProt resource (available in the public domain at www.uniprot.org).

Phenotypic Characterization of V83I POAG Cases

Phenotypic data for 1070 AA POAG cases were extracted from the POAAGG study’s Research Electronic Data Capture (REDCap) database,12 and cases were grouped for analysis by MTCO1 genotypes: m.6150G (V83 wild type), m.6150G>A (V83I mutation), m.6548C (V83 wild type), and m.6548C>T (V83 wild type, with silent substitution, L215L, indicative of African haplogroup L1b).

The masked comparison included 29 cases with V83I and M117T (“double missense”) mutations, associated with mtDNA haplogroup L1c2. “Triple missense” cases, possessing a third variant, V193I, associated with an L1c2 sublineage, L1c2b1b, were excluded. The control group included 29 cases with the L1b-associated silent substitution (m.6548C>T, L215L) and lacking all three missense variants. Each L1c2 case was paired with an L1b control case having the same sex and reported family history of glaucoma (yes or no), and similar age at enrollment into the POAAGG study. Haplogroup was masked during chart review.

The following data were collected from the medical records: demographic characteristics, including age, sex, family history of glaucoma; glaucoma phenotypes at visit closest to enrollment, including ICD-9 codes for glaucoma severity, maximum IOP, visual acuity, central corneal thickness (CCT), retinal nerve fiber layer thickness (RNFLT) on OCT, CDR, mean deviation (MD), and pattern standard deviation (PSD) on Humphrey visual field test. A 20% cutoff for false-positive and false-negative response rates and fixation losses was used for visual fields, and the OCT with the best signal strength (minimum 7/10) was chosen for each patient. We used both eyes for this analysis, adjusting for the correlation between eyes.

Yeast Two-Hybrid (Y2H) Studies

All Y2H studies were performed by Hybrigenics Services (available in the public domain at www.hybrigenics-services.com, Paris, France). The coding sequence of the human MT-CO1 fragment (amino acids 41–101, GenBank accession number gi: 251851109) was PCR-amplified and cloned into vectors pB27 and pB66 as C-terminal fusions to LexA (LexA-
MT-CO1:V83I is a POAG Risk Factor for African American Men

CO1) and the Gal4 DNA-binding domain (Gal4-CO1), respectively. Codon use of the CO1 insert was optimized for yeast expression, and to prevent spurious amino acid changes caused by differences in the human mitochondrial and yeast nuclear genetic codes. The constructs were checked by sequencing, and used as a bait to screen a randomly-primed Human Adult Brain cDNA library constructed19 into pP6, using RNA from a 27-year-old male (D6030-15, lot A308079; Invitrogen, Carlsbad, CA, USA). Vector pB27 derives from the original pBTM116 vector,20 pB66 derives from the original pAS2 ΔA vector21 and pB6 is based on the pGADGHI plasmid.22

The N-Gal4-CO1-C bait construct was used for the cDNA library screen, and 47 million clones, 4-fold the complexity of the library, were screened using a mating approach23 with YHGX13 (Y187 ade2-101::loxP-kanMX-loxP, matz) and CG1945 (mata) yeast strains. A total of 323 His103 colonies were selected on a medium lacking tryptophan, leucine, and histidine. The prey fragments of the positive clones were amplified by PCR on a medium lacking tryptophan, leucine, and histidine. The MT-CO1 (mata) yeast strains. A total of 323 His103 original pBTM116 vector, 20 pB66 derives from the original Invitrogen, Carlsbad, CA, USA). Vector pB27 derives from the original pBTM116 vector,20 pB66 derives from the original pAS2 ΔA vector21 and pB6 is based on the pGADGHI plasmid.22

Interaction pairs were tested in triplicate, using a growth assay. For each interaction, several dilutions (10^0/C0 3, 10^2/C0 10^4 cells) and expressing bait and prey constructs were spotted on several selective media. The different dilutions also were used as negative controls for evaluating interaction with β. Sandwich ELISA was performed by binding Aβ1-42 or scrambled Aβ1-42 to the plate overnight at 4°C, followed by blocking with 5% nonfat dry milk and 1% BSA for 90 minutes at room temperature (RT). After blocking, the wells were incubated with biotinylated wild-type type-Cox1 peptide, Biotinylated-Mut (V83I)-Cox1 peptide, ApoE protein (positive control) or TBX3 (negative control) for two hours at RT. Each experimental well was washed thrice with 1X TBST for 5 minutes at RT. The interacting complex was detected by incubation with Avidin-peroxidase conjugate followed by ABTS (50 μl/well) for color development. Approximately 30 μl/well of 1% SDS in PBS with Tween 20 (PBST) was added to stop the color development and the ELISA plate was read at 410 nm in an ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA). All ELISA experiments were done in triplicate.

Statistical Analysis
All P values were calculated using Fisher’s exact test, except for phenotypic characteristics, which were calculated using logistic regression, with generalized estimating equations (GEE)25 to account for correlation between eyes for ocular characteristics. All analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results
Characteristics of the Study Population
Phenotypic data from 1070 AA POAG cases were analyzed, and the majority (59%) of these subjects were female. The mean age of wild type (V83) cases was 71.1 years, vs. 70.8 years for V83I cases (P = 0.81). Sanger sequencing of the m.6150 region of MT-CO1 was obtained for 2189 AA individuals (1339 POAG cases, 850 controls), and 4.5% possessed the V83I mutation. The 850 non-POAG controls also were mostly female (65%) but significantly younger (61 ± 11.8 years, P < 0.001) than the POAG group. The total number of cases sequenced was larger than 1070 because an additional 269 cases were sequenced subsequent to phenotypic analysis.

Sequencing Identified Additional Missense Variants in MT-CO1
Sanger sequencing of the N-terminal region of MT-CO1 identified 21 missense variants, in addition to the three variants detected previously in the POAGG cohort (m.6150G>A [V83], m.6253T>C [M117T], m.6480G>A [V193I]; Supplemental Table S1).10,11 None of the missense variants differed significantly between cases and controls; however, most were
Table 1. Association of MT-CO1 Variants With POAG in AA Males and Females

<table>
<thead>
<tr>
<th>Variant</th>
<th>Combined</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Genotype</td>
<td>OR (95% CI)</td>
<td>P Value</td>
</tr>
<tr>
<td></td>
<td>Case</td>
<td>Control</td>
<td></td>
</tr>
<tr>
<td>m.6150</td>
<td>GA, V83I</td>
<td>72 (5.4%)</td>
<td>26 (3.1%)</td>
</tr>
<tr>
<td></td>
<td>G, V85</td>
<td>1267 (94.6%)</td>
<td>824 (96.9%)</td>
</tr>
<tr>
<td>T&gt;C, M117T</td>
<td>60 (4.5%)</td>
<td>24 (2.8%)</td>
<td>1.6 (1.0, 2.7)</td>
</tr>
<tr>
<td>T, M117</td>
<td>1279 (95.5%)</td>
<td>827 (97.2%)</td>
<td>P = 0.05</td>
</tr>
<tr>
<td>m.6480</td>
<td>G&gt;A, V193I</td>
<td>14 (1.0%)</td>
<td>2 (0.2%)</td>
</tr>
<tr>
<td></td>
<td>G, V193</td>
<td>1323 (99.0%)</td>
<td>851 (99.8%)</td>
</tr>
<tr>
<td>C&gt;T, L215L</td>
<td>118 (8.9%)</td>
<td>80 (9.4%)</td>
<td>0.9 (0.7, 1.3)</td>
</tr>
<tr>
<td>C, L215</td>
<td>1213 (91.1%)</td>
<td>773 (90.6%)</td>
<td>P = 0.70</td>
</tr>
</tbody>
</table>

Association of Four MT-CO1 Variants With POAG in AA Males and Females

Common mtDNA variants are associated with one or more mtDNA lineages (haplogroups), with African haplogroups represented by the letter “L”, with L0, L1, L2, L4, and so forth representing the deepest branches. Supplementary Figure S1 depicts the mtDNA family tree in schematic form, and indicates the relative divergence times of selected MT-CO1 variants, including V83I (mostly L1c2 haplogroup). V83I also is found in a subset of POAGG subjects belonging to an L2 haplogroup (not shown); these subjects possessed an L2-associated variant, m.2416T>C in the MFRNR2 gene, but lacked the L1c2-associated variant M117T. The synonymous variant, m.6548C>T (L215L), which is associated with the relative divergence times of selected MT-CO1 variants, including V83I (mostly L1c2 haplogroup), was used as the reference group (Table 2). When analyzed separately by sex, mean PD was higher in V83I males and V83I females, but the difference was significant in males (P = 0.047), but not females. Despite this difference, the V83I patients had significantly lower IOP (P = 0.01). Mean CCT was higher in the V83I group, but this difference was not significant. However, the distribution of CCT across three bins was nominally significant (P = 0.049), with the largest fraction of V83I patients having CCT greater than 540 μm. The V83I cases, 73% reported a positive family history of glaucoma, versus 57% of V83 (wild type) cases, and this difference was statistically significant (P = 0.03). Maternal family history of glaucoma also was reported more often in V83I cases (35% vs. 20% for V83 wild type, P = 0.03).

Female cases outnumbered male cases in the cohort as a whole, by approximately 1.5:1, whereas the V83I group contained nearly equal numbers of males and females. In other words, the V83I case group was disproportionately male. The mean age at enrollment of V83I cases was 68.8 years for males and 72.8 for females, versus 70.1 and 71.8, respectively, in the corresponding wildtype (V83) groups. Mean age did not differ significantly between the V83I and wildtype groups (P = 0.58 and P = 0.65 for males and females, respectively) Prostate cancer was noted more frequently in the V83I group, 10.2% vs. 5.6%, but this difference was not significant, and likely explained by the higher proportion of males in the V83I group. The L215L (m.6548C>T) reference group, representing haplogroup L1b and lacking all three missense variants, differed significantly only in that it was disproportionately female (P = 0.049), and had a significantly lower incidence of prostate cancer (P = 0.04). This is presumably due to a larger proportion of females in the L215L group (data not shown).

Masked Chart Reviews of Haplogroup L1c2 (V83I + M117T) Versus L1b Patients

Because the V83I patients had significantly worse visual function than V83 (wild type) patients, despite lower IOP, we performed a masked chart review, focused on L1c2 patients (n = 29). In order to control for non-L1 mtDNA ancestry, patients from the L1b haplogroup (wild type for V83 and M117) were used as the reference group (n = 29). The two groups also were matched for age, sex, and family history of POAG (yes or no) to control for these potential confounders. The chart review was conducted with a fellowship-trained glaucoma specialist (AL). In parallel with the chart review, we determined that the L1c2 group had significantly worse...
disease, as assessed by ICD-9 codes for glaucoma severity previously entered in the electronic medical records. Of the L1c2 cases having disease stage codes, 81% had "severe" disease (ICD-9 365.73) as opposed to 17% of L1b cases (P = 0.002, Table 3). The L1c2 group had significantly higher mean CDR (P = 0.04) and worse visual function as assessed by average PSD (P = 0.009) and MD (P = 0.006) at the visit closest to diagnosis (Table 4). IOP was lower in the L1c2 group despite their worse disease, although the difference did not reach statistical significance (P = 0.07). CCT (not shown) did not differ significantly between the L1c2 and L1b groups.

### Table 2. Phenotypic Characteristics of AA POAG Cases With and Without the V83I Mutation

<table>
<thead>
<tr>
<th>Characteristic (Eyes Or Cases)</th>
<th>Level</th>
<th>V83 (Wild Type)</th>
<th>V83I (Mutant)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IOP, Mm Hg, eyes</td>
<td>&lt;21</td>
<td>655 (33.0%)</td>
<td>42 (45.3%)</td>
<td>0.14†</td>
</tr>
<tr>
<td>21–24</td>
<td>436 (22.0%)</td>
<td>24 (24.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;24</td>
<td>895 (45.1%)</td>
<td>51 (52.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>25.3 (8.5)</td>
<td>22.7 (7.0)</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>CCT, μm, eyes</td>
<td>&lt;500</td>
<td>359 (20.2%)</td>
<td>27 (31.0%)</td>
<td>0.049†</td>
</tr>
<tr>
<td>500–540</td>
<td>776 (43.7%)</td>
<td>24 (27.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;540</td>
<td>641 (36.1%)</td>
<td>36 (41.4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>529 (39.0)</td>
<td>530 (45.1)</td>
<td>0.95</td>
<td></td>
</tr>
<tr>
<td>PSD, dB, eyes</td>
<td>&lt;3</td>
<td>480 (42.7%)</td>
<td>22 (29.7%)</td>
<td>0.11†</td>
</tr>
<tr>
<td>3–7</td>
<td>330 (29.4%)</td>
<td>22 (29.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;7</td>
<td>313 (27.9%)</td>
<td>30 (40.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>5.0 (3.5)</td>
<td>6.3 (4.1)</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>MD, dB, eyes</td>
<td>&lt;–5</td>
<td>474 (42.4%)</td>
<td>43 (59.7%)</td>
<td>0.007†</td>
</tr>
<tr>
<td>–5–0</td>
<td>505 (45.2%)</td>
<td>18 (25.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;0</td>
<td>138 (12.4%)</td>
<td>11 (15.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>–7.1 (9.4)</td>
<td>–10.4 (10.8)</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Family history of glaucoma, cases</td>
<td>Negative</td>
<td>424 (42.6%)</td>
<td>13 (27.1%)</td>
<td>0.03</td>
</tr>
<tr>
<td>Positive</td>
<td>571 (57.4%)</td>
<td>35 (72.9%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal family history of glaucoma, cases</td>
<td>Negative</td>
<td>818 (80.1%)</td>
<td>33 (67.3%)</td>
<td>0.03</td>
</tr>
<tr>
<td>Positive</td>
<td>203 (19.9%)</td>
<td>16 (32.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex, cases</td>
<td>Male</td>
<td>410 (40.2%)</td>
<td>25 (51.0%)</td>
<td>0.13</td>
</tr>
<tr>
<td>Female</td>
<td>611 (59.8%)</td>
<td>24 (49.0%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

† P value represents distribution across three levels.

disease, as assessed by ICD-9 codes for glaucoma severity previously entered in the electronic medical records. Of the L1c2 cases having disease stage codes, 81% had “severe” disease (ICD-9 365.73) as opposed to 17% of L1b cases (P = 0.002, Table 3).

The L1c2 group had significantly higher mean CDR (P = 0.04) and worse visual function as assessed by average PSD (P = 0.009) and MD (P = 0.006) at the visit closest to diagnosis (Table 4). IOP was lower in the L1c2 group despite their worse disease, although the difference did not reach statistical significance (P = 0.07). CCT (not shown) did not differ significantly between the L1c2 and L1b groups.

### Subcellular Localization of V83, M117 and V193 Amino Acid Residues

Sequence analysis by UniProt predicted the V83I replacement affects a residue located on the inner side of the inner mitochondrial membrane, which is exposed to the mitochondrial matrix, whereas M117T and V193I were predicted to be located inside the mitochondrial inner membrane. The domain organization of the CO1 protein and locations of these residues are depicted in Supplementary Figure S2. The reported Aβ-interacting region of the CO1 protein, which includes V83, spans an intermembrane, transmembrane, and mitochondrial matrix region.

### Y2H test of CO1/Aβ Interaction, and cDNA Library Screen For CO1 Interactors

We could not demonstrate the protein–protein interaction of CO1 and Aβ in the Y2H system. Accordingly, we were unable to perform a Y2H test of CO1 and Aβ and could not screen for CO1 interactors.

### Table 3. Glaucma Severity Codes (ICD-9) of Matched L1c2 vs. L1b POAG Cases

<table>
<thead>
<tr>
<th>Glaucoma Stage (ICD-9 code)</th>
<th>L1c2 Cases, n = 29</th>
<th>L1b Cases, n = 29</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unspecified (365.70)</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Mild (365.71)</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Moderate (365.72)</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Severe (365.73)</td>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>No ICD-9 code</td>
<td>4</td>
<td>8</td>
</tr>
</tbody>
</table>

"Figure." ELISA assay for interaction of mutant and wild type CO1 peptides with Aβ1–42 or scrambled Aβ1–42. APOE protein was the positive control, and TBX3 protein and scrambled Aβ peptide (ScrAβ1–42) were negative controls.
to study the effect of the V83I amino acid replacement on the CO1/Aβ interaction by Y2H, and used an ELISA assay instead, described below. The screen of the human adult brain cDNA library, using an N-terminal CO1 wild type (V83) fragment as bait, retrieved seven unique clones containing fragments of ubiquilin1, the product of the UBQLN1 gene. The Predicted Biological Score19 for these Y2H interactions were classified as “very high confidence,” and UBQLN1 is a known interactor and chaperone of mitochondrial membrane proteins.

### Quantification of Wild Type and Mutant (V83I) CO1 Fragment With UBQLN1 Fragment in the Y2H System

The CO1 (WT)/UBQLN1 interaction was confirmed to be very strong; however, the mutant CO1 (V83I)/UBQLN1 interaction was equally strong, so V83I did not affect this interaction in the Y2H system. Both interactions resisted up to 10 mM 3-AT (α-aminotriazole) (Supplementary Figure S3). The CO1 (WT)/UBQLN1 interaction was found to interact very weakly with Aβ (Fig.). At the highest peptide concentrations tested, V83I reduced the interaction by 92%, to a level comparable to the negative control. However, the mutant CO1 (V83I) peptide had similar lack of affinity for the scrambled Aβ negative control peptides, suggesting the interaction of CO1 and Aβ is specific, and is disrupted by V83I. We were unable to study the interaction of CO1 peptide with the fragment of UBQLN1 retrieved in the cDNA library screen by ELISA, on account of an inability to synthesize the hydrophobic UBQLN1 peptide.

### Interaction of CO1 and Aβ Peptides

The reported affinity of wild type CO1 (V83) peptide for Aβ1–42 was confirmed by ELISA, whereas mutant CO1 (V83I) was found to interact very weakly with Aβ (Fig.). At the highest peptide concentrations tested, V83I reduced the interaction by 92%, to a level comparable to the negative control. However, wild type and mutant (V83I) CO1 peptides had similar lack of affinity for the scrambled Aβ negative control peptides, suggesting the interaction of CO1 and Aβ is specific, and is disrupted by V83I. We were unable to study the interaction of CO1 peptide with the fragment of UBQLN1 retrieved in the cDNA library screen by ELISA, on account of an inability to synthesize the hydrophobic UBQLN1 peptide.

### DISCUSSION

#### Male-Female Dimorphism in POAG

The association of sex with POAG is controversial with only some studies finding men at higher risk; however, a recent meta-analysis concluded men are at 1.3-fold higher risk of POAG than women.24 Leber’s hereditary optic neuropathy (LHON) was the first disease shown to be caused by missense mutations in mtDNA, resulting in defects in mitochondrial energy production.25 LHON, like POAG, involves familial degeneration of the optic nerve. LHON affects males much more severely than females, with higher penetrance and an earlier age of onset in males. Most LHON cases are caused by three mtDNA pathogenic variants (m.3460G>A in MT-ND1, m.11778G>A in MT-FND4, or m.14484T>C in MT-FND6), all with incomplete penetrance and with a risk of symptoms developing ranging from 1.7- to 7.7-fold higher in men versus women (available in the public domain at https://www.ncbi.nlm.nih.gov/books/NBK1174/). The association of m.6150G>A (V83I) in MFCO1 with POAG also exhibited an extreme male sex bias, with an OR 5.9-fold higher in men than in women (Table 1). Inheritance of mitochondria is matrilineal, so natural selection of mitochondria occurs only in females, and sex-specific phenotypes may not have fitness consequences for mitochondria, resulting in female-male asymmetry in disease severity.26

A recent study of nuclear SNPs near 9p21 reported a significantly stronger association with normal tension glaucoma in females (OR 1.5) than males (OR 1.35).27 Collectively these findings suggest that the genetic architecture of POAG for males and females may differ substantially, with penetrance differing by sex. Male-female dimorphism in response to overexpression of mutant amyloid precursor protein has been reported in a mouse model of AD, with complex IV activity consistently higher in female control mice.14

### The V83I POAG Phenotype

The V83I patients had worse visual function and degeneration of the optic nerve, despite lower IOP, even after controlling for age, sex, family history of POAG, AA ancestry, and L1 mtDNA haplogroup. This evidence is consistent with the proposal that the V83I missense mutation may contribute to POAG pathogenesis, and these patients may be more vulnerable to POAG in general, and at lower IOP than other AAs. Interestingly, a study of the association of mtDNA variations with dementia risk and Aβ in elderly AAs found African mitochondrial haplogroup L1 participants were at elevated risk for dementia (OR, 1.88; P = 0.004), lower plasma Aβ1–42 levels (P = 0.03), and greater risk for intellectual decline, relative to the most common AA haplogroup, L3.28

### Potential Functional Effects of MT-CO1 Missense Variants

Cytochrome c oxidase is a “bigenomic” protein machine with components encoded by the nuclear and mitochondrial genomes. The mtDNA-encoded proteins, for example, CO1, are functionally constrained by the requirement to interact with nuclear proteins. The three POAG-associated missense mutations may occur either alone, for example, V83I on an L2 mtDNA background, or in combination, for example, V83I and M117T on L1c2-related haplogroups, which also may carry V193I (Supplementary Figure S1). M117T has been predicted to be pathogenic based on 3D structural modeling suggesting it participates in bigenomic protein–protein interactions, and might influence the stability of Complex IV.29 The V193I variant originally was detected in a patient having cytochrome c oxidase deficiency, and was proposed to be pathogenic, based on its absence in 300 controls.30 However, V193I now is based on its absence in 300 controls.30 However, V193I now is
proposed as a “helper” variant, acting in synergy with the primary LHON mutation, m.11778G>A, in a Chinese family. V193I, like M117T, may affect interactions with Complex IV proteins encoded by nuclear genes. V83I is the stronger candidate for a functional variant in addition to a marker for POAG susceptibility. The association of V83I with POAG in AA men was stronger than for M117T or V193I (Table 1). This is because the association of V83I with POAG stemmed not only from L1c2 subjects also having M117T, but also from additional L2 haplogroup subjects who have V83I, but lack the other two missense mutations. V83I also is the only one of these mutations within the Aβ-binding region, and we showed this replacement greatly abrogated this interaction in the ELISA assay (Fig.). Another reported prostate cancer-linked mutation (M74T, m.6124T>C) is located nine residues from V83. This mutation was not observed in POAGG subjects; however, it also is within the Aβ-binding region, and was shown to be functional, causing resistance to statin-induced apoptosis, increase reactive oxygen production, and enhanced cellular proliferation. M74T cybrid cells had a significantly faster doubling time than wild type cells. So it is reasonable to speculate that V83I or other nearby CO1 mutations also might influence cellular proliferation, albeit negatively, thereby promoting neurodegeneration. The retrieval of UBQLN1, a neuroprotective AD- and Aβ-associated gene, by yeast two-hybrid analysis suggests this region may function in the recognition of CO1 for sequestration by ubiquilins and degradation by the proteasome.

Potential for Interactions Among CO1, Aβ, and Ubiquilin-1

The POAG-associated V83I CO1 mutation diminished the interaction with Aβ1–42 in the ELISA assay (Fig.). CO1 and Aβ1–42 have been shown to coprecipitate from mitochondria of human neuroblastoma cells, so this interaction appears to occur in vivo. These observations suggest the interaction of soluble Aβ with CO1 is normal and potentially beneficial, whereas aggregation of Aβ may cause mitochondrial dysfunction, including oxidative damage by reactive oxygen species, induction of apoptosis and ion channel formation.

The yeast two-hybrid library screen, using the Aβ-interacting region of CO1 as “bait” retrieved an AD-associated gene, ubiquilin1 (UBQLN1). UBQLN1 functions as a molecular chaperone of the amyloid precursor protein (APP), and modulates the intracellular trafficking of APP. Knockdown of UBQLN1 results in increased levels of Aβ. Sequence variation in UBQLN1 has been associated with AD, and overexpression of some UBQLN1 transcript variants exerts neuroprotective effects via the unfolded protein response (UPR). Ubiquilins, including UBQLN1, recently have been shown to chaperone and triage mitochondrial membrane proteins for degradation by the proteasome, suggesting the CO1/UBQLN1 interaction might occur in the cytosol, for example as a response to the release of CO1 from damaged mitochondria. The region of UBQLN1 retrieved by the two hybrid screen (amino acids 108–388) overlaps with the N-terminal part of its “M domain” (amino acids 180–470), which is required for binding transmembrane domains of mitochondrial membrane proteins. Genetic ablation of ubiquilins results in the accumulation of noninserted mitochondrial membrane protein precursors in the cytosol. UBQLN1 has not been implicated in POAG, but was among a small number of antiapoptotic genes found to be upregulated by platelet derived growth-factor CC, which protects retinal ganglion cells (RGC) from death in optic nerve crush-injured mouse retinae.

Mechanisms for Mitochondrial Dysfunction in Glaucoma and AD

Glucoma and AD have several features in common, including increasing incidence with age and loss of specific neuronal subpopulations. Glaucoma is more prevalent among Down syndrome patients, who have an extra copy of the APP gene, encoding Aβ. Down syndrome cases are prone to glaucoma development before the age of 40 and at normal pressure, in addition to early-onset AD. This is consistent with overlapping molecular etiologies for AD and glaucoma involving Aβ. Intramitochondrial Aβ may directly cause neurotoxicity and mitochondrial dysfunction, including impairment of OXPHOS and interaction with mitochondrial proteins. Aβ is known to localize to the mitochondrial matrix and inner mitochondrial membrane, so there is a potential for Aβ to interact directly with Complex IV, which it is known to inhibit.

Neuronal mitochondria offer potential targets for therapies that support mitochondrial function. Complex IV is a target for interventions that may protect RGCs from death as a result of glaucoma. For example, methylene blue has been shown to protect rat RGCs from toxic insults to mitochondria, such as rotenone, which can cause optic neuropathy. Administration of near-infrared light also is neuroprotective, possibly via the same mechanism as methylene blue: transfer of electrons directly to Complex IV. It was shown recently that Aβ-induced mitochondrial dysfunction involves the forkhead box O3a FOXO3A gene, which is present in neuronal mitochondria, binds mtDNA, and leads to decreased MITCO1 expression, so there also may be indirect influences of Aβ on Complex IV.

Glucomatous changes might arise from multiple mechanisms of mitochondrial damage, some of which might involve Aβ in addition to changes in mtDNA and nuclear genes. These factors might act alone, or in concert with elevated IOP which may damage mitochondria directly. For example, elevated pressure causes release of cytochrome c and OPAl release in RGC-5 cells, resulting in apoptotic cell death. Mitochondrial damage from IOP also was demonstrated in glaucomatous DBA/2J mice, where elevated IOP resulted in mitochondrial fission, matrix swelling, cytochrome c release, and a moderate reduction of expression of MITCO1 mRNA. Oxidative stress caused by ozone exposure has been shown to increase Aβ1–42 production and accumulation of Aβ1–42 in mitochondria, with colocalization of OPAl, Aβ, and CO1. Increased expression of Aβ and abnormal APP metabolism is associated with RGC apoptosis in experimental glaucoma models, with colocalization of Aβ with apoptotic RGCs.

Limitations of This Study

The association of V83I with POAG in AA men may be explained by unknown functional factors associated with the corresponding mtDNA lineages (primarily L1c2 and L2 lineages) and/or by population stratification of the POAGG study population. Additional work will be required to determine whether V83I or other mutations directly influence Complex IV activity or confer other functional phenotypes, and to assess the potential for involvement of UBQLN1 in POAG pathogenesis.

Conclusions

Because V83I is associated predominately with African mitochondrial ancestries (L1c2, L2, and others), this variant may contribute to the relatively high POAG risk in AAs. V83I...
MT-CO1:V83I is a POAG Risk Factor for African American Men

mtDNA and the antioxidant mitotempo have been shown to disrupt a previously reported protein-protein interaction with Aβ, which could be significant in light of proposals that the etiology of POAG may overlap with other neurodegenerative conditions, particularly AD, with Aβ common to both. We propose that CO1 also interacts with UBQLN1, and that UBQLN1, which is a potential therapeutic target for AD, may also be relevant to POAG.

Interventions to treat optic neuropathies by supporting mitochondrial function are under development. Recently, metformin and the antioxidant mitotempo have been shown to protect human neural stem cells and cultured mouse neurons, respectively, against Aβ-induced mitochondrial dysfunction. Alternatively, emerging gene-based therapies now offer the ability to correct deleterious germline alterations in mtDNA.

Acknowledgments

The authors thank Jie He for assistance with sequencing mtDNA, and Guishuang Ying and Rebecca Salove for helpful suggestions during preparation of the manuscript. Supported by the National Eye Institute (1R01EY023557-01), National Eye Institute Vision Core Grant (P30 EY01585-26), and National Institutes of Health (NIH: LM010098; Bethesda, MD, USA), as well as the F.M. Kirby Foundation, Research to Prevent Blindness, UPenn Hospital Board of Women Visitors, Paul Mackall and Evanna Bell MacKall Trust, and National Eye Institute, NIH, Department of Health and Human Services, under eyeGENE (contracts #HHSN260202700001C and HHSN262201200001C), and the Department of Ophthalmology at the University of Pennsylvania.

Disclosure: W.T. Merritt III, None; W.T. Merritt IV, None; W.T. Merritt V, None; W.T. Merritt VI, None; W.T. Merritt VII, None; R.A. Rossii, None; Blachon, None; P.S. Sankar, None; A. Lehman, None; V. Addis, None; J.M. O'Brien, None

References


